FexoTopic Portfolio
A diversified portfolio focused on fexofenadine, encompassing 6 drug concepts covering up to 12 indications with a high therapeutic index.
Fexofenadine as a Platform
Fexofenadine's well-characterized safety profile and multi-modal mechanism of action make it an ideal platform molecule for drug repurposing. Our portfolio leverages decades of clinical experience with fexofenadine to develop new formulations targeting conditions where current treatments are inadequate.
Drug Concepts
OP2101
Topical fexofenadine for atopic dermatitis — lead candidate in phase 1 clinical development.
OP2102
Oral formulation optimized for chronic spontaneous urticaria with enhanced bioavailability.
OP2103
Topical formulation targeting psoriasis-related inflammation and itch.
OP2104
Novel delivery system for rosacea and inflammatory skin conditions.
OP2105
Combination therapy approach for severe atopic dermatitis.
OP2106
Extended-release formulation for chronic inflammatory conditions.
Target Indications
Interested in Our Portfolio?
Whether you are an investor, partner, or researcher, we welcome conversations about our pipeline and collaboration opportunities.
Get in Touch